Clearmind Medicine Inc.

NasdaqCM CMND

Clearmind Medicine Inc. Price to Earnings Ratio (P/E) on December 30, 2024: -0.84

Clearmind Medicine Inc. Price to Earnings Ratio (P/E) is -0.84 on December 30, 2024, a -18.83% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Clearmind Medicine Inc. 52-week high Price to Earnings Ratio (P/E) is -0.55 on January 23, 2024, which is 34.91% above the current Price to Earnings Ratio (P/E).
Clearmind Medicine Inc. 52-week low Price to Earnings Ratio (P/E) is -1.46 on July 15, 2024, which is -74.13% below the current Price to Earnings Ratio (P/E).
Clearmind Medicine Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -0.80.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: CMND

Clearmind Medicine Inc.

CEO	Dr. Adi Zuloff-Shani Ph.D.
IPO Date	Nov. 15, 2022
Location	Canada
Headquarters	1220 West 6th Avenue
Employees	4
Sector	Health Care
Industries Pharmaceuticals Mental Health

Description

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Key trends

Past 5 years